Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome

International Journal of Clinical Oncology
Takayuki Ishikawa

Abstract

Myelodysplastic syndrome (MDS) is a clonal hematopoietic neoplasm with high rates of leukemic transformation. MDS had been an intractable disease for which the mainstream of therapeutic approach was best supportive care. Recently, however, treatment of hematological malignancies has benefited from advances in molecular targeted drug discovery such as the revolutionary drug imatinib for chronic myeloid leukemia, and from the reappraisal of forgotten drugs such as thalidomide for multiple myeloma. Two azanucleotide drugs, azacitidine (AZA) and decitabine, were created as anti-neoplastic drugs in the 1960s with little success. In the 1980s, they were reassessed as hypomethylating agents (HMAs), and the introduction of low-dose schedules of them has shown dramatic effects in the delay of leukemic evolution for high-risk MDS. AZA was approved in Japan in March 2011 and has become a standard drug of choice in the treatment of high-risk MDS. Its position as a treatment for low-risk MDS remains to be established. Only half of patients with high-risk MDS can gain benefit from AZA. For example, those with complex karyotypes experience only a limited extension in survival. In addition, AZA resistance develops sooner or later. To achieve a...Continue Reading

References

Aug 1, 1976·Annals of Internal Medicine·D D Von HoffF M Muggia
Jan 1, 1985·Pharmacology & Therapeutics·R L MomparlerM Gyger
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Dec 31, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bart L ScottH Joachim Deeg
Jun 2, 2005·Leukemia Research·Hui YangGuillermo Garcia-Manero
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger M LyonsC L Beach
Nov 6, 2009·The New England Journal of Medicine·Ayalew Tefferi, James W Vardiman
Feb 13, 2010·Cancer·Pellegrino MustoUNKNOWN Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias
Apr 1, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mikkael A SekeresJaroslaw P Maciejewski
Jun 1, 2011·Cancer Science·Toshiki UchidaTomomitsu Hotta
Jul 27, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas PrébetNorbert Vey
Sep 29, 2011·Seminars in Oncology·Simrit ParmarRichard Champlin
Jan 19, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Aaron T GerdsBart L Scott
Oct 12, 2012·International Journal of Hematology·Seishi Ogawa
Apr 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carla FilìDomenico Russo
Aug 21, 2013·Blood Reviews·Amer M ZeidanSteven D Gore

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Lewis R SilvermanJames F Holland
Zhongguo shi yan xue ye xue za zhi
Qing-Jie Hu, Bao-An Chen
Cancer Control : Journal of the Moffitt Cancer Center
Steven D Gore, Evelyn R Hermes-DeSantis
Best Practice & Research. Clinical Haematology
Richard A Larson
© 2021 Meta ULC. All rights reserved